

Tab E

THE WHITE HOUSE
WASHINGTON

May 16, 1994

Dr. Edouard Sakiz
Chairman, Supervisory Board
Roussel Uclaf
35, boulevard des Invalides
75323 Paris Cedex 07
FRANCE

Dear Dr. Sakiz:

It is important for the health of women in the United States that they have access to the widest possible range of safe and effective medical treatments. In support of that goal, in January 1993, I asked the Secretary of Health and Human Services to promote the testing and licensing of mifepristone (RU 486) and other antiprogestins in the United States. *file*

I understand that since at least that time, your company has been in negotiations with The Population Council, Inc., a nonprofit organization with whom you have had dealings on mifepristone since early in the last decade. Those discussions, I understand, have been directed toward the purpose on which I charged the Secretary. I am grateful for the effort those negotiations represent.

In order to permit the appropriate testing, development, and distribution of your product, I urge, at the conclusion of your negotiations, that you bring your plans to fruition. I understand that your company will assign without remuneration your United States patent rights on mifepristone to The Population Council, Inc. which has been studying this product since 1982 and which would take all necessary steps to file a new drug application with the Food and Drug Administration, so that the agency can determine whether the drug is safe and effective for use in the United States.

On behalf of the government of the United States and for the women in America, I thank you for your work.

Sincerely,

Bill Clinton